FDA Delays Skyrizi Review for Crohn's; U.S. Transplant System on Notice; SABR in HCC – Medpage Today

by Zaina Hamza, Staff Writer, MedPage Today
The FDA extended its review period for risankizumab (Skyrizi) for a proposed indication in Crohn’s disease by 3 months, in order to review additional data including information on an on-body injector, drugmaker AbbVie announced.
Over one-fourth of Crohn’s disease patients with complete endoscopic healing still reported moderate to severe disability. (Clinics and Research in Hepatology and Gastroenterology)
A new report from the National Academies of Sciences, Engineering, and Medicine concludes that the U.S. needs an overhaul to address its “inequitable” organ transplant system, and argues that Congress should hold the Department of Health and Human Services accountable so that changes are made in the next 5 years.
In the U.S., non-alcoholic steatohepatitis (NASH) is the top indication for liver transplants among the elderly, according to a study of the Scientific Registry of Transplant Recipients. (Hepatology Communications)
Hepatitis B virus surface antigen titers in childhood predicted progression to liver fibrosis in later life. (Clinical Gastroenterology and Hepatology)
Researchers in Australia are launching a randomized trial to investigate sterotactic ablative body radiotherapy as a non-invasive alternative to standard percutaneous ablation for inoperable early-stage hepatocellular carcinoma (HCC). (Flinders University)
The 5-year survival rate following curative surgery for HCC was 48% in North America, lower than the global average of 56.2%, a large meta-analysis found. (Hepatology Communications)
“Today” show anchor Craig Melvin discussed losing his brother to colon cancer. (The DRS)
Zaina Hamza is a staff writer for MedPage Today, covering Gastroenterology and Infectious disease. She is based in Chicago.
Primary Source
(Spike)
Source Reference:
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
© 2022 MedPage Today, LLC. All rights reserved.
Medpage Today is among the federally registered trademarks of MedPage Today, LLC and may not be used by third parties without explicit permission.

source

Leave a Comment

Your email address will not be published.

Shopping Cart